All In Biotech

Drug Trial Radar · NCT02066415

A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Chronic Migraine Prevention

Last checked: Nov 20, 2026Latest source record: Oct 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 667 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

667

Actual

Start

Mar 5, 2014

Primary completion

Feb 24, 2016

Study completion Apr 28, 2016

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Feb 19, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the effect of erenumab compared to placebo on the change from baseline in the number of monthly migraine days in adults with chronic migraine.

Conditions

  • Treatment for Prevention of Chronic Migraine

Interventions

  • ErenumabBiological

    Administered once a month subcutaneously by authorized investigational site study staff.

  • PlaceboDrug

    Administered once a month subcutaneously by authorized investigational site study staff.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Monthly Migraine DaysTime frame: 4-week baseline phase and the last 4 weeks of the 12-week treatment phase

Locations

74 sites in 10 countries. Site status is shown where the registry gives one.

  • Research Site

    La Jolla, California

  • Research Site

    Newport Beach, California

  • Research Site

    San Francisco, California

  • Research Site

    Santa Monica, California

  • Research Site

    Sherman Oaks, California

  • Research Site

    Stanford, California

  • Research Site

    Stamford, Connecticut

  • Research Site

    Jacksonville, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Palm Beach Gardens, Florida

  • Research Site

    West Palm Beach, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Decatur, Georgia

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Pikesville, Maryland

  • Research Site

    Watertown, Massachusetts

  • Research Site

    Worcester, Massachusetts

  • Research Site

    Ann Arbor, Michigan

  • Research Site

    Kalamazoo, Michigan

  • Research Site

    Springfield, Missouri

  • Research Site

    St Louis, Missouri

  • Research Site

    Reno, Nevada

  • Research Site

    Amherst, New York

  • Research Site

    Greensboro, North Carolina

  • Research Site

    Cleveland, Ohio

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Nashville, Tennessee

  • Research Site

    Austin, Texas

  • Research Site

    Dallas, Texas

  • Research Site

    Dallas, Texas

  • Research Site

    Temple, Texas

  • Research Site

    Virginia Beach, Virginia

  • Research Site

    Seattle, Washington

  • Research Site

    Milwaukee, Wisconsin

  • Research Site

    Calgary, Alberta, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Brno, Czechia

  • Research Site

    Brno, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Prague, Czechia

Showing 40 of 74 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.